European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Lumykras, sotorasib, Date of authorisation: 06/01/2022, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 12:50

Human medicines European public assessment report (EPAR): Lumykras, sotorasib, Date of authorisation: 06/01/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Vitrakvi, larotrectinib, Date of authorisation: 19/09/2019, Revision: 18, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 12:44

Human medicines European public assessment report (EPAR): Vitrakvi, larotrectinib, Date of authorisation: 19/09/2019, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Plerixafor Accord, plerixafor, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 12:40

Human medicines European public assessment report (EPAR): Plerixafor Accord, plerixafor, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Braftovi, encorafenib, Date of authorisation: 19/09/2018, Revision: 18, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 11:55

Human medicines European public assessment report (EPAR): Braftovi, encorafenib, Date of authorisation: 19/09/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Zeffix, lamivudine, Date of authorisation: 29/07/1999, Revision: 32, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 11:48

Human medicines European public assessment report (EPAR): Zeffix, lamivudine, Date of authorisation: 29/07/1999, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 11:08

Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Nucala, mepolizumab, Date of authorisation: 01/12/2015, Revision: 28, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 11:02

Human medicines European public assessment report (EPAR): Nucala, mepolizumab, Date of authorisation: 01/12/2015, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Zonegran, zonisamide, Date of authorisation: 10/03/2005, Revision: 38, Status: Authorised

Submitted by Anonymous (not verified) on 22 July 2026 - 10:55

Human medicines European public assessment report (EPAR): Zonegran, zonisamide, Date of authorisation: 10/03/2005, Revision: 38, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More